广西医学
廣西醫學
엄서의학
GUANGXI MEDICAL JOURNAL
2014年
2期
173-176
,共4页
陈昕妤%胡晓桦%罗小玲%包雯光%秦柳霄%李永强%刘志辉%梁嵘
陳昕妤%鬍曉樺%囉小玲%包雯光%秦柳霄%李永彊%劉誌輝%樑嶸
진흔여%호효화%라소령%포문광%진류소%리영강%류지휘%량영
肝细胞癌%吉西他滨%化疗%回顾性分析
肝細胞癌%吉西他濱%化療%迴顧性分析
간세포암%길서타빈%화료%회고성분석
Hepatocellular carcinoma%Gemcitabine%Chemotherapy%Retrospective study
目的:评估吉西他滨( GEM)为主的化疗方案治疗晚期原发性肝细胞癌的疗效和安全性。方法晚期原发性肝细胞癌患者89例用GEM为主方案进行化疗,其中GEM+优氟泰( UFT )41例, GEM+奥沙利铂(L-OHP)48例。按照RECIST 1.1版标准评估疗效,按照CTCAE3.0的毒性标准评估化疗不良反应。结果86例可评价疗效,客观有效率(ORR)及疾病控制率(DCR)分别为19.8%和50.0%;中位生存期为6.2个月,累积半年生存率为53.5%,1年生存率为23.3%,2年生存率为3.5%。 GEM+UFT方案与GEM+L-OHP方案的ORR、DCR及中位生存期分别为20.0%、19.6%;47.5%、52.2%;6.0个月、6.3个月,差异无统计学意义(P均>0.05)。两组不良反应发生率比较,差异无统计学意义( P均>0.05)。结论 GEM为主的联合方案治疗晚期肝癌有较好的临床疗效,不良反应可耐受;GEM联合优氟泰方案与GEM联合奥沙利铂方案疗效相似,但前者使用较方便。
目的:評估吉西他濱( GEM)為主的化療方案治療晚期原髮性肝細胞癌的療效和安全性。方法晚期原髮性肝細胞癌患者89例用GEM為主方案進行化療,其中GEM+優氟泰( UFT )41例, GEM+奧沙利鉑(L-OHP)48例。按照RECIST 1.1版標準評估療效,按照CTCAE3.0的毒性標準評估化療不良反應。結果86例可評價療效,客觀有效率(ORR)及疾病控製率(DCR)分彆為19.8%和50.0%;中位生存期為6.2箇月,纍積半年生存率為53.5%,1年生存率為23.3%,2年生存率為3.5%。 GEM+UFT方案與GEM+L-OHP方案的ORR、DCR及中位生存期分彆為20.0%、19.6%;47.5%、52.2%;6.0箇月、6.3箇月,差異無統計學意義(P均>0.05)。兩組不良反應髮生率比較,差異無統計學意義( P均>0.05)。結論 GEM為主的聯閤方案治療晚期肝癌有較好的臨床療效,不良反應可耐受;GEM聯閤優氟泰方案與GEM聯閤奧沙利鉑方案療效相似,但前者使用較方便。
목적:평고길서타빈( GEM)위주적화료방안치료만기원발성간세포암적료효화안전성。방법만기원발성간세포암환자89례용GEM위주방안진행화료,기중GEM+우불태( UFT )41례, GEM+오사리박(L-OHP)48례。안조RECIST 1.1판표준평고료효,안조CTCAE3.0적독성표준평고화료불량반응。결과86례가평개료효,객관유효솔(ORR)급질병공제솔(DCR)분별위19.8%화50.0%;중위생존기위6.2개월,루적반년생존솔위53.5%,1년생존솔위23.3%,2년생존솔위3.5%。 GEM+UFT방안여GEM+L-OHP방안적ORR、DCR급중위생존기분별위20.0%、19.6%;47.5%、52.2%;6.0개월、6.3개월,차이무통계학의의(P균>0.05)。량조불량반응발생솔비교,차이무통계학의의( P균>0.05)。결론 GEM위주적연합방안치료만기간암유교호적림상료효,불량반응가내수;GEM연합우불태방안여GEM연합오사리박방안료효상사,단전자사용교방편。
Objective To evaluate the efficacy and safety of chemotherapy based on gemcitabine ( GEM) for the treatment of advanced primary hepatocellular carcinoma .Methods Eight-nine patients with advanced primary hepatocellular carcinoma recieved chemotherapy based on GEM ,including 41 cases treated with GEM plus UFT and 48 cases treated with GEM plus L-OHP.The efficacy was assessed based on RECIST 1.1,and the adverse events were evaluated according to CTCAE 3.0.Results Eight-six patients were assessable for efficacy .The objective response rate(ORR),disease control rate(DCR) were 19.8%and 50.0%,respectively;The median survival was 6.2 months;The cumulative half-a-year,1-year,2-year survival rates were 53.5%,23.3%and 3.5%,respectively.The ORR,DCR and median survival showed no significant difference between GEM +UFT group and GEM+L-OHP group(20.0%vs. 19.6%,47.5% vs.52.2%,6.0 months vs.6.3 months,all P>0.05).The adverse reactions showed no significant difference between two groups (all P>0.05).Conclusion The combination chemotherapy based on GEM is of good clinical efficacy for the treatment of advanced primary hepatocellular carcinoma ,and the adverse reactions could be tolerated . The efficiency of GEM+UFT regimen is similar to that of GEM +L-OHP regimen ,but the former regimen is of simpler operation.